Cost-effectiveness of Teriflunomide Compared to Interferon Beta-1b for Relapsing Multiple Sclerosis Patients in China
ConclusionTeriflunomide is a cost-effective therapy over a lifetime time horizon compared to interferon beta-1b in the treatment of RMS patients in China. Results should be interpreted with caution as head-to-head comparisons are not available.
Source: Clinical Drug Investigation - Category: Drugs & Pharmacology Source Type: research
More News: Betaseron | Brain | China Health | Disability | Drugs & Pharmacology | Multiple Sclerosis | Neurology | Study